Gao et al. compared haploidentical and matched-sibling mDLI, followed by low-dose CsA (median: 2.3◊107 CD3+ cells/kg for the entire cohort), in high-risk AML defined by progressive disease at transplant, CR1 achievement with ≥3 cycles of chemotherapy, or those carrying TP53, DNMT3a, TET2, or FLT3-ITD gene mutations. This evidence concerns the gene TP53 and acute myeloid leukemia.